Bovie Medical (NYSEMKT:BVX), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the third quarter of fiscal year 2018 will be released after the market closes on Thursday, November 1.

Management will host a conference call at 4:30 p.m. Eastern Time on November 1 to discuss the results of the quarter and to host a question and answer session. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 6375776. Participants should ask for the Bovie Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at: https://event.on24.com/wcc/r/1822306/45823D187A3462B4AEEA8EC718B8449B.

A telephonic replay will be available approximately two hours after the end of the call through November 15, 2018. The replay can be accessed by dialing 800-585-8367 for U.S. callers or 416-621-4642 for international callers and using the replay access code: 6375776. The webcast will be archived on the Investor Relations section of the Company’s website.

About Bovie Medical Corporation

Bovie Medical Corporation is a medical technology company and the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma technology utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Bovie Medical Corporation website at www.boviemedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005857/en/